File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients
  • Basic View
  • Metadata View
  • XML View
TitleCirculating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients
 
AuthorsYeung, DCY1 1
Xu, A1 1 1
Tso, AWK1 1
Chow, WS1
Wat, NMS1
Fong, CHY1
Tam, S2
Sham, PC1
Lam, KSL1 1
 
Issue Date2009
 
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
 
CitationDiabetes Care, 2009, v. 32 n. 1, p. 132-134 [How to Cite?]
DOI: http://dx.doi.org/10.2337/dc08-1333
 
AbstractOBJECTIVE - To investigate the relationships of serum adipocyte fatty acid-binding protein (A-FABP) and epidermal fatty acid-binding protein (E-FABP) with renal dysfunction and macrovascular complications in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- The associations of serum A-FABP and E-FABP with markers of renal function, nephropathy staging, and macrovascular complications were examined in 237 type 2 diabetic patients. RESULTS - Serum A-FABP and E-FABP correlated significantly with serum creatinine, mean albumin excretion rate, and glomerular filtration rate (all P < 0.001) and were independently associated with diabetic nephropathy staging (P = 0.001 and P < 0.05, respectively). Circulating levels of both types of FABP were increased (P < 0.01) in subjects with macrovascular complications. Serum A-FABP was independently associated with macrovascular complications (odds ratio 2.92 [95% CI 1.42-6.01]; P = 0.004). CONCLUSIONS - Serum A-FABP and E-FABP might be novel serum biomarkers for evaluating the progression of nephropathy and its cardiovascular risk in type 2 diabetic patients. © 2009 by the American Diabetes Association.
 
ISSN0149-5992
2012 Impact Factor: 7.735
2012 SCImago Journal Rankings: 3.758
 
DOIhttp://dx.doi.org/10.2337/dc08-1333
 
ISI Accession Number IDWOS:000262188000029
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYeung, DCY
 
dc.contributor.authorXu, A
 
dc.contributor.authorTso, AWK
 
dc.contributor.authorChow, WS
 
dc.contributor.authorWat, NMS
 
dc.contributor.authorFong, CHY
 
dc.contributor.authorTam, S
 
dc.contributor.authorSham, PC
 
dc.contributor.authorLam, KSL
 
dc.date.accessioned2010-05-31T03:47:58Z
 
dc.date.available2010-05-31T03:47:58Z
 
dc.date.issued2009
 
dc.description.abstractOBJECTIVE - To investigate the relationships of serum adipocyte fatty acid-binding protein (A-FABP) and epidermal fatty acid-binding protein (E-FABP) with renal dysfunction and macrovascular complications in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- The associations of serum A-FABP and E-FABP with markers of renal function, nephropathy staging, and macrovascular complications were examined in 237 type 2 diabetic patients. RESULTS - Serum A-FABP and E-FABP correlated significantly with serum creatinine, mean albumin excretion rate, and glomerular filtration rate (all P < 0.001) and were independently associated with diabetic nephropathy staging (P = 0.001 and P < 0.05, respectively). Circulating levels of both types of FABP were increased (P < 0.01) in subjects with macrovascular complications. Serum A-FABP was independently associated with macrovascular complications (odds ratio 2.92 [95% CI 1.42-6.01]; P = 0.004). CONCLUSIONS - Serum A-FABP and E-FABP might be novel serum biomarkers for evaluating the progression of nephropathy and its cardiovascular risk in type 2 diabetic patients. © 2009 by the American Diabetes Association.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationDiabetes Care, 2009, v. 32 n. 1, p. 132-134 [How to Cite?]
DOI: http://dx.doi.org/10.2337/dc08-1333
 
dc.identifier.citeulike3824291
 
dc.identifier.doihttp://dx.doi.org/10.2337/dc08-1333
 
dc.identifier.epage134
 
dc.identifier.hkuros154217
 
dc.identifier.isiWOS:000262188000029
 
dc.identifier.issn0149-5992
2012 Impact Factor: 7.735
2012 SCImago Journal Rankings: 3.758
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid18931100
 
dc.identifier.scopuseid_2-s2.0-64549103470
 
dc.identifier.spage132
 
dc.identifier.urihttp://hdl.handle.net/10722/59337
 
dc.identifier.volume32
 
dc.languageeng
 
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofDiabetes Care
 
dc.relation.referencesReferences in Scopus
 
dc.titleCirculating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yeung, DCY</contributor.author>
<contributor.author>Xu, A</contributor.author>
<contributor.author>Tso, AWK</contributor.author>
<contributor.author>Chow, WS</contributor.author>
<contributor.author>Wat, NMS</contributor.author>
<contributor.author>Fong, CHY</contributor.author>
<contributor.author>Tam, S</contributor.author>
<contributor.author>Sham, PC</contributor.author>
<contributor.author>Lam, KSL</contributor.author>
<date.accessioned>2010-05-31T03:47:58Z</date.accessioned>
<date.available>2010-05-31T03:47:58Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Diabetes Care, 2009, v. 32 n. 1, p. 132-134</identifier.citation>
<identifier.issn>0149-5992</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/59337</identifier.uri>
<description.abstract>OBJECTIVE - To investigate the relationships of serum adipocyte fatty acid-binding protein (A-FABP) and epidermal fatty acid-binding protein (E-FABP) with renal dysfunction and macrovascular complications in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- The associations of serum A-FABP and E-FABP with markers of renal function, nephropathy staging, and macrovascular complications were examined in 237 type 2 diabetic patients. RESULTS - Serum A-FABP and E-FABP correlated significantly with serum creatinine, mean albumin excretion rate, and glomerular filtration rate (all P &lt; 0.001) and were independently associated with diabetic nephropathy staging (P = 0.001 and P &lt; 0.05, respectively). Circulating levels of both types of FABP were increased (P &lt; 0.01) in subjects with macrovascular complications. Serum A-FABP was independently associated with macrovascular complications (odds ratio 2.92 [95% CI 1.42-6.01]; P = 0.004). CONCLUSIONS - Serum A-FABP and E-FABP might be novel serum biomarkers for evaluating the progression of nephropathy and its cardiovascular risk in type 2 diabetic patients. &#169; 2009 by the American Diabetes Association.</description.abstract>
<language>eng</language>
<publisher>American Diabetes Association. The Journal&apos;s web site is located at http://diabetes.diabetesjournals.org/</publisher>
<relation.ispartof>Diabetes Care</relation.ispartof>
<title>Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0149-5992&amp;volume=32&amp;spage=132&amp;epage=4&amp;date=2009&amp;atitle=Circulating+levels+of+adipocyte+and+epidermal+fatty+acid-binding+proteins+in+relation+to+nephropathy+staging+and+macrovascular+complications+in+type+2+diabetic+patients</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.2337/dc08-1333</identifier.doi>
<identifier.pmid>18931100</identifier.pmid>
<identifier.scopus>eid_2-s2.0-64549103470</identifier.scopus>
<identifier.hkuros>154217</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-64549103470&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>32</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>132</identifier.spage>
<identifier.epage>134</identifier.epage>
<identifier.isi>WOS:000262188000029</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.citeulike>3824291</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. Queen Mary Hospital Hong Kong